Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shinogi

Pfizer finally acquires the @pfizer name on Twitter

Will streamline its existing @pfizer_news account

- PMLiVE

GSK hit as darapladib flunks phase III test

Heart disease drug disappoints in late-stage trial

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

- PMLiVE

Electric dreams in medicine

Treating human disease with electrical impulses dates back decades, and now pharma is exploring the concept of ‘electroceuticals’ to complement drug-based therapy

- PMLiVE

Pfizer sales down but oncology shows promise

Toll of patent expiries continues

- PMLiVE

GSK sets up centre to develop greener drugs

Brazil centre to focus on sustainable chemistry

- PMLiVE

China weighs heavy on GSK figures in Q3

Pharma company loses two thirds of sales in region after scandal-hit period

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

Pfizer calls for mHealth to be prioritised

Wants more action to support mobile health in developing countries' ageing populations

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links